Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

• Status: Completed
• Trial end date: 2001-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to assess the effect of NNC 90-1170 on beta-cell responsiveness to increasing blood glucose concentrations in subjects with type 2 diabetes.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Diagnosed with type 2 diabetes, either newly diagnosed with at least 2 months of diet or on OAD monotherapy for at least 3 months

• Body Mass Index (BMI): 24-35 kg/m^2 inclusive

Exclusion Criteria:

• SUBJECTS WITH TYPE 2 DIABETES

• Receipt of any investigational drug within three months prior to this trial

• Recurrent severe hypoglycemia as judged by the investigator

• Cardiac disease

• Use of any drug (except an OAD (oral anti-diabetic drug)) that in the investigator's opinion could interfere with the blood glucose level

• Haemoglobin maximum 10 g/L

• HbA1c above 12%

• Loss of more than 400 mL blood during the 3 months prior to trial start

• HEALTHY SUBJECTS

• Receipt of any investigational drug within 3 months prior to this trial

• Clinically relevant cardiac disease or any clinically significant abnormal ECG (electrocardiogram)

• Use of any drug that in the investigator's opinion could interfere with the blood glucose level

• Haemoglobin max. 10 g/L

• HbA1c at least 6%